ASSEMBLY BIOSCIENCES, INC.ASMBEarnings & Financial Report
Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.
ASMB Q3 2025 Key Financial Metrics
Revenue
$10.8M
Gross Profit
N/A
Operating Profit
$-10.9M
Net Profit
$-9.2M
Gross Margin
N/A
Operating Margin
-100.9%
Net Margin
-85.2%
YoY Growth
57.6%
EPS
$-0.72
Financial Flow
ASSEMBLY BIOSCIENCES, INC. Q3 2025 Financial Summary
ASSEMBLY BIOSCIENCES, INC. reported revenue of $10.8M for Q3 2025, with a net profit of $-9.2M (-85.2% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $10.8M |
|---|---|
| Net Profit | $-9.2M |
| Gross Margin | N/A |
| Operating Margin | -100.9% |
| Report Period | Q3 2025 |
ASSEMBLY BIOSCIENCES, INC. Annual Revenue by Year
ASSEMBLY BIOSCIENCES, INC. annual revenue history includes year-by-year totals (for example, 2024 revenue was $28.5M).
| Year | Annual Revenue |
|---|---|
| 2024 | $28.5M |
| 2023 | $7.2M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.2M | $5.8M | $8.5M | $6.8M | $7.4M | $9.4M | $9.6M | $10.8M |
| YoY Growth | N/A | N/A | N/A | N/A | 2.7% | 62.8% | 12.8% | 57.6% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $136.8M | $119.9M | $115.3M | $100.3M | $119.2M | $99.0M | $80.8M | $240.0M |
| Liabilities | $95.7M | $87.3M | $80.6M | $74.3M | $85.8M | $71.9M | $62.7M | $57.3M |
| Equity | $41.1M | $32.6M | $34.7M | $26.0M | $33.4M | $27.1M | $18.1M | $182.7M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $73.6M | $-18.4M | $-17.1M | $-15.2M | $-407000 | $-23.4M | $-16.8M | $-15.1M |
More Companies
CRSP
CRISPR Therapeutics AG
Revenue
$864.0K
Net Profit
$-130.6M
GRAL
GRAIL, Inc.
Revenue
$36.2M
Net Profit
$-89.0M
RCUS
Arcus Biosciences, Inc.
Revenue
$6.0M
Net Profit
$-135.0M
TXG
10x Genomics, Inc.
Revenue
$166.0M
Net Profit
$-16.3M
DFTX
Mind Medicine (MindMed) Inc.
Revenue
$906.0K
Net Profit
$-23.9M
PACB
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Revenue
$38.4M
Net Profit
$-38.0M
DTIL
PRECISION BIOSCIENCES INC
Revenue
$13.0K
Net Profit
$-21.8M